| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Division of Pulmonary, Critical Care, and Sleep Medicine, Dept of Medicine, School of Medicine and Biomedical Sciences and the Veterans Affairs Medical Center, and 2 School of Pharmacy, University at Buffalo, Buffalo, NY, USA.
CORRESPONDENCE: A. A. El Solh, Division of Pulmonary, Critical Care, and Sleep Medicine, Erie County Medical Center, 462 Grider Street, Buffalo, NY 14215, USA. Fax: 1 7168986139. E-mail: solh{at}buffalo.edu
Keywords: Allopurinol, endothelium, free radicals, sleep apnoea
Received: August 27, 2005
Accepted December 19, 2005
Increased oxidative stress in obstructive sleep apnoea is thought to contribute to endothelial dysfunction. The objective of this study was to test the hypothesis that inhibition of xanthine oxidase by allopurinol can improve endothelial function in patients with obstructive sleep apnoea.
A randomised double-blind placebo-controlled crossover study was performed on 12 patients with moderate-to-severe obstructive sleep apnoea, comparing 300 mg allopurinol daily for 2 weeks with placebo. Endothelial function was assessed using hyperaemia-induced flow-mediated vasodilation (FMD) at baseline and following treatment. Plasma malondialdehyde levels were compared in order to assess significant changes in oxidative stress.
Baseline FMD correlated significantly with the severity of sleep apnoea and the time spent with an arterial oxygen saturation of <90%. Allopurinol caused a significant increase in FMD compared to placebo (10.4±3.2 versus 7.4±2.8%, respectively). Plasma malondialdehyde levels were significantly reduced with allopurinol treatment (1.5±0.3 versus 1.2±0.3 µmol·L–1), consistent with reduced oxidative stress.
Allopurinol improves endothelial dysfunction in patients with moderate-to-severe obstructive sleep apnoea. These observations suggest that xanthine oxidase contributes significantly to vasodilatory impairment.
This article has been cited by other articles:
|
|
 |
|
  A. Boueiz, M. Damarla, and P. M. Hassoun Xanthine oxidoreductase in respiratory and cardiovascular disorders Am J Physiol Lung Cell Mol Physiol, May 1, 2008; 294(5): L830 - L840. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Gozal and L. Kheirandish-Gozal Cardiovascular Morbidity in Obstructive Sleep Apnea: Oxidative Stress, Inflammation, and Much More Am. J. Respir. Crit. Care Med., February 15, 2008; 177(4): 369 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. El Solh, M. E. Akinnusi, F. H. Baddoura, and C. R. Mankowski Endothelial Cell Apoptosis in Obstructive Sleep Apnea: A Link to Endothelial Dysfunction Am. J. Respir. Crit. Care Med., June 1, 2007; 175(11): 1186 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Teramoto, H. Kume, Y. Yamaguchi, H. Yamamoto, Y. Hanaoka, M. Ishii, T. Ishii, and Y. Ouchi Improvement of endothelial function with allopurinol may occur in selected patients with OSA: effect of age and sex Eur. Respir. J., January 1, 2007; 29(1): 216 - 217. [Full Text] [PDF]
|
|
|
|
|
|
A. A. El Solh From the authors Eur. Respir. J., January 1, 2007; 29(1): 217 - 218. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
